FRI0247 Median time to low disease activity is shorter in tocilizumab combination therapy with csdmards as compared to monotherapy in patients with active rheumatoid arthritis and inadequate responses to csdmards and/or tnf inhibitors: subanalysis of the swiss and austrian patients from the act-sure study